Crossref Citations
This article has been cited by the following publications. This list is generated based on data provided by
Crossref.
Lewis Metcalfe, Whitney E.
Washington, Nicole B.
and
Brahm, Nancy
2013.
Treatment of antipsychotic-induced hyperprolactinemia with bromocriptine: A case report.
Mental Health Clinician,
Vol. 3,
Issue. 3,
p.
162.
Karow, Anne
Wittmann, Linus
Schöttle, Daniel
Schäfer, Ingo
and
Lambert, Martin
2014.
The assessment of quality of life in clinical practice in patients with schizophrenia.
Dialogues in Clinical Neuroscience,
Vol. 16,
Issue. 2,
p.
185.
Prigent, Amélie
Auraaen, Ane
Kamendje-Tchokobou, Blaise
Durand-Zaleski, Isabelle
and
Chevreul, Karine
2014.
Health-Related Quality of Life and Utility Scores in People with Mental Disorders: A Comparison with the Non-Mentally Ill General Population.
International Journal of Environmental Research and Public Health,
Vol. 11,
Issue. 3,
p.
2804.
Michel, Pierre
Auquier, Pascal
Baumstarck, Karine
Loundou, Anderson
Ghattas, Badih
Lançon, Christophe
and
Boyer, Laurent
2015.
How to interpret multidimensional quality of life questionnaires for patients with schizophrenia?.
Quality of Life Research,
Vol. 24,
Issue. 10,
p.
2483.
Lecardeur, L.
2015.
La qualité de vie en schizophrénie.
L'Encéphale,
Vol. 41,
Issue. 4,
p.
373.
Guthrie, Susan
Bienkowska-Gibbs, Teresa
Manville, Catriona
Pollitt, Alexandra
Kirtley, Anne
and
Wooding, Steven
2015.
The impact of the National Institute for Health Research Health Technology Assessment programme, 2003–13: a multimethod evaluation.
Health Technology Assessment,
Vol. 19,
Issue. 67,
p.
1.
Lasebikan, V. O.
and
Owoaje, E. T.
2015.
Quality of Life in Psychosis: Prevalence and Associated Factors in a Nigerian Clinical Population.
Community Mental Health Journal,
Vol. 51,
Issue. 4,
p.
491.
Boucekine, Mohamed
Boyer, Laurent
Baumstarck, Karine
Millier, Aurelie
Ghattas, Badih
Auquier, Pascal
and
Toumi, Mondher
2015.
Exploring the Response Shift Effect on the Quality of Life of Patients with Schizophrenia.
Medical Decision Making,
Vol. 35,
Issue. 3,
p.
388.
Zemmour, K.
Tinland, A.
Boucekine, M.
Girard, V.
Loubière, S.
Resseguier, N.
Fond, G.
Auquier, P.
Boyer, L.
Apostolidis, T.
Birmes, P.
Bossetti, T.
Bouloudnine, R.
Combes, B.
Debieve, J.
Falissard, B.
Greacen, T.
Laval, C.
Lancon, C.
Le Cardinal, P.
Mantovani, J.
Moreau, D.
Naudin, J.
Rhunter, P.
and
Videau, B.
2016.
Validation of the Medication Adherence Rating Scale in homeless patients with schizophrenia: Results from the French Housing First experience.
Scientific Reports,
Vol. 6,
Issue. 1,
Karow, Anne
Bullinger, Monika
and
Lambert, Martin
2016.
Beyond Assessment of Quality of Life in Schizophrenia.
p.
123.
El-Mallakh, Peggy
and
Findlay, Jan
2016.
Improving Treatment Adherence in Schizophrenia.
Current Treatment Options in Psychiatry,
Vol. 3,
Issue. 2,
p.
119.
Moran, Katherine
and
Priebe, Stefan
2016.
Better quality of life in patients offered financial incentives for taking anti-psychotic medication: Linked to improved adherence or more money?.
Quality of Life Research,
Vol. 25,
Issue. 8,
p.
1897.
Awad, George
Ng-Mak, Daisy
Rajagopalan, Krithika
Hsu, Jay
Pikalov, Andrei
and
Loebel, Antony
2016.
Long-term health-related quality of life improvements among patients treated with lurasidone: results from the open-label extension of a switch trial in schizophrenia.
BMC Psychiatry,
Vol. 16,
Issue. 1,
Iasevoli, Felice
Fagiolini, Andrea
Formato, Maria Vittoria
Prinzivalli, Emiliano
Giordano, Sara
Balletta, Raffaele
De Luca, Vincenzo
and
de Bartolomeis, Andrea
2017.
Assessing patient-rated vs. clinician-rated adherence to the therapy in treatment resistant schizophrenia, schizophrenia responders, and non-schizophrenia patients.
Psychiatry Research,
Vol. 249,
Issue. ,
p.
159.
Pai, Nagesh
and
Warden, Matthew
2018.
Early Australian experience in the maintenance of schizophrenia management with 3-monthly paliperidone palmitate.
Australasian Psychiatry,
Vol. 26,
Issue. 6,
p.
628.
Schmidt, Stefanie J.
Lange, Matthias
Schöttle, Daniel
Karow, Anne
Schimmelmann, Benno G.
and
Lambert, Martin
2018.
Negative symptoms, anxiety, and depression as mechanisms of change of a 12-month trial of assertive community treatment as part of integrated care in patients with first- and multi-episode schizophrenia spectrum disorders (ACCESS I trial).
European Archives of Psychiatry and Clinical Neuroscience,
Vol. 268,
Issue. 6,
p.
593.
Arikawa, Masatoshi
Ota, Kazumi
and
Azekawa, Takaharu
2019.
The influence of psychiatric day care on the continuation of treatment for patients with schizophrenia: A retrospective cohort study in Japan.
Social Work in Mental Health,
Vol. 17,
Issue. 5,
p.
615.
Julaeha, Julaeha
Athiyah, Umi
and
Hermansyah, Andi
2019.
The prescription patterns of second-generation antipsychotics in schizophrenia outpatient setting.
Journal of Basic and Clinical Physiology and Pharmacology,
Vol. 30,
Issue. 6,
Shehu, Ado
Garba, Saleh Ngaski
Anyebe, Emmanuel Ejembi
Tukur, Mb
and
Gomma, Hayat
2019.
Adherence to drug treatment among schizophrenic patients in Jigawa State, Nigeria.
Annals of African Medical Research,
Vol. 2,
Issue. 1,
Phillips, Katie M.
Hoehle, Lloyd P.
Caradonna, David S.
Gray, Stacey T.
and
Sedaghat, Ahmad R.
2020.
Intranasal corticosteroids and saline: Usage and adherence in chronic rhinosinusitis patients.
The Laryngoscope,
Vol. 130,
Issue. 4,
p.
852.
Comments
No Comments have been published for this article.